Literature DB >> 20443898

Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.

Hong I Wan1, J Steve Jacobsen, J Lynn Rutkowski, Giora Z Feuerstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20443898      PMCID： PMC5350742          DOI： 10.1111/j.1752-8062.2009.00121.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN： 1752-8054            Impact factor:   4.689


× No keyword cloud information.
  25 in total

1.  Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

Authors:  Dirk Beher; Earl E Clarke; Jonathan D J Wrigley; Agnes C L Martin; Alan Nadin; Ian Churcher; Mark S Shearman
Journal:  J Biol Chem       Date:  2004-08-10       Impact factor: 5.157

2.  Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation.

Authors:  Alberto Lleó; Oksana Berezovska; Lauren Herl; Susan Raju; Amy Deng; Brian J Bacskai; Matthew P Frosch; Michael Irizarry; Bradley T Hyman
Journal:  Nat Med       Date:  2004-09-26       Impact factor: 53.440

3.  Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Authors:  E R Siemers; J F Quinn; J Kaye; M R Farlow; A Porsteinsson; P Tariot; P Zoulnouni; J E Galvin; D M Holtzman; D S Knopman; J Satterwhite; C Gonzales; R A Dean; P C May
Journal:  Neurology       Date:  2006-02-28       Impact factor: 9.910

4.  Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.

Authors:  Randall J Bateman; Ling Y Munsell; John C Morris; Robert Swarm; Kevin E Yarasheski; David M Holtzman
Journal:  Nat Med       Date:  2006-06-25       Impact factor: 53.440

5.  Selective inhibition of Abeta42 production by NSAID R-enantiomers.

Authors:  T Morihara; T Chu; O Ubeda; W Beech; G M Cole
Journal:  J Neurochem       Date:  2002-11       Impact factor: 5.372

6.  Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.

Authors:  Thomas A Lanz; Michael J Karmilowicz; Kathleen M Wood; Nikolay Pozdnyakov; Ping Du; Mary A Piotrowski; Tracy M Brown; Charles E Nolan; Karl E G Richter; James E Finley; Qing Fei; Charles F Ebbinghaus; Yuhpyng L Chen; Douglas K Spracklin; Barbara Tate; Kieran F Geoghegan; Lit-Fui Lau; David D Auperin; Joel B Schachter
Journal:  J Pharmacol Exp Ther       Date:  2006-08-18       Impact factor: 4.030

7.  Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice.

Authors:  Lisa McConlogue; Manuel Buttini; John P Anderson; Elizabeth F Brigham; Karen S Chen; Stephen B Freedman; Dora Games; Kelly Johnson-Wood; Michael Lee; Michelle Zeller; Weiqun Liu; Ruth Motter; Sukanto Sinha
Journal:  J Biol Chem       Date:  2007-07-06       Impact factor: 5.157

8.  Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.

Authors:  Robert L Martone; Hua Zhou; Kevin Atchison; Thomas Comery; Jane Z Xu; Xinyi Huang; Xioahai Gong; Mei Jin; Anthony Kreft; Boyd Harrison; Scott C Mayer; Suzan Aschmies; Cathleen Gonzales; Margaret M Zaleska; David R Riddell; Erik Wagner; Peimin Lu; Shaiu-Ching Sun; June Sonnenberg-Reines; Aram Oganesian; Karissa Adkins; Michael W Leach; David W Clarke; Donna Huryn; Magid Abou-Gharbia; Ronald Magolda; Jonathan Bard; Glen Frick; Sangeeta Raje; S Bradley Forlow; Carrie Balliet; Michael E Burczynski; Peter H Reinhart; Hong I Wan; Menelas N Pangalos; J Steven Jacobsen
Journal:  J Pharmacol Exp Ther       Date:  2009-08-11       Impact factor: 4.030

9.  Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage.

Authors:  Thomas Kukar; Todd E Golde
Journal:  Curr Top Med Chem       Date:  2008       Impact factor: 3.295

10.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.

Authors:  R Sherrington; E I Rogaev; Y Liang; E A Rogaeva; G Levesque; M Ikeda; H Chi; C Lin; G Li; K Holman; T Tsuda; L Mar; J F Foncin; A C Bruni; M P Montesi; S Sorbi; I Rainero; L Pinessi; L Nee; I Chumakov; D Pollen; A Brookes; P Sanseau; R J Polinsky; W Wasco; H A Da Silva; J L Haines; M A Perkicak-Vance; R E Tanzi; A D Roses; P E Fraser; J M Rommens; P H St George-Hyslop
Journal:  Nature       Date:  1995-06-29       Impact factor: 49.962
View more
  12 in total

1.  Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).

Authors:  Walter J Lukiw
Journal:  Expert Opin Emerg Drugs       Date:  2012-03-23       Impact factor: 4.191

Review 2.  The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease.

Authors:  Jiahong Sun; Jan Michelle Martin; Victoria Vanderpoel; Rachita K Sumbria
Journal:  Neuromolecular Med       Date:  2019-01-17       Impact factor: 3.843

Review 3.  Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease.

Authors:  Lezanne Ooi; Kuldip Sidhu; Anne Poljak; Greg Sutherland; Michael D O'Connor; Perminder Sachdev; Gerald Münch
Journal:  J Neural Transm (Vienna)       Date:  2012-06-13       Impact factor: 3.575

4.  First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.

Authors:  Tomas Borgegard; Anders Juréus; Fredrik Olsson; Susanne Rosqvist; Alan Sabirsh; Didier Rotticci; Kim Paulsen; Rebecka Klintenberg; Hongmei Yan; Magnus Waldman; Kia Stromberg; Johan Nord; Jonas Johansson; Anna Regner; Santiago Parpal; David Malinowsky; Ann-Cathrin Radesater; Tingsheng Li; Rajeshwar Singh; Hakan Eriksson; Johan Lundkvist
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

Review 5.  Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing.

Authors:  Jiansong Fang; Andrew A Pieper; Ruth Nussinov; Garam Lee; Lynn Bekris; James B Leverenz; Jeffrey Cummings; Feixiong Cheng
Journal:  Med Res Rev       Date:  2020-07-13       Impact factor: 12.944

Review 6.  Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects.

Authors:  Robert Vassar; Peer-Hendrik Kuhn; Christian Haass; Matthew E Kennedy; Lawrence Rajendran; Philip C Wong; Stefan F Lichtenthaler
Journal:  J Neurochem       Date:  2014-04-19       Impact factor: 5.372

Review 7.  Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors.

Authors:  Marton Siklos; Manel BenAissa; Gregory R J Thatcher
Journal:  Acta Pharm Sin B       Date:  2015-09-26       Impact factor: 11.413

Review 8.  Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.

Authors:  Jeffrey Cummings; Aaron Ritter; Kate Zhong
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 9.  Modeling Alzheimer's Disease with Induced Pluripotent Stem Cells: Current Challenges and Future Concerns.

Authors:  Weiwei Zhang; Bin Jiao; Miaojin Zhou; Tao Zhou; Lu Shen
Journal:  Stem Cells Int       Date:  2016-05-24       Impact factor: 5.443

Review 10.  Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes.

Authors:  Jeffrey Cummings
Journal:  Clin Transl Sci       Date:  2017-08-02       Impact factor: 4.689
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.